Cancer Genetics Inc

Cancer Genetics — Investor Presentation (September 2015)

27 slides from Cancer Genetics's investor presentation, Sep 23, 2015

  1. Slide 1: The Oncology Diagnostics Partner from Bench to Bedside

    THE ONCOLOGY DIAGNOSTICS PARTNER FROM BENCH TO BEDSIDE Investor Presentation NASDAQ: CGIX September 2015

  2. Slide 2: Forward-Looking Statements

    INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, f

  3. Slide 3: Investor Highlights

    INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 3 Large, Global Market Opportunities $458B GLOBAL ONCOLOGY SPEND BY 2030 Global Footprint Created by Highly Strategic M&A 3 TRANSFORMATIVE ACQUISITIONS IN 2014–2015 Strong & Growing Partnerships with Leadi

  4. Slide 4: Our Mission

    INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 4 CLINICAL TRIALSRESEARCH PATIENT CARE OUR MISSION IS TO BE THE ONCOLOGY DIAGNOSTICS PARTNER OF CHOICE FROM BENCH TO BEDSIDE PARTNERING WITH LEADING RESEARCH INSTITUTIONS TO DRIVE INNOVATION AND DEVELOP NE

  5. Slide 5: Uniquely Positioned to Address Macro-Trends in Oncology

    INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 5 UNIQUELY POSITIONED TO ADDRESS MACRO-TRENDS IN ONCOLOGY INCREASING GLOBAL NEED FOR IMPROVED DIAGNOSIS AND MANAGEMENT GLOBAL FOOTPRINT DEEP, DISEASE-FOCUSED GENOMIC KNOWLEDGE & INSIGHTS PROVEN DISEASE-KNO

  6. Slide 6: Global Oncology Market Forecast & Potential

    INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 6 2014 2018 GLOBAL ONCOLOGY MARKET FORECAST & POTENTIAL GLOBAL SPENDING ($ IN BILLIONS) US EU5 JAPAN PHARMERGING ROW Source: IMS Health MIDAS, Dec. 2014; IMS Health Market Prognosis, March 2015. Oncology i

  7. Slide 7: Key M&A Criteria and Acquisitions

    INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 7 KEY M&A CRITERIA ACQUISITIONS GLOBAL FOOTPRINT Response Genetics, Inc. (Pending 2015)  Leading solid tumor testing franchise with content in lung, colorectal, skin and brain cancers as well as FDA-clear

  8. Slide 8: Response Genetics Acquisition Highlights

    INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 8 COMBINED PORTFOLIO COVERS 8 OF THE 10 MOST PREVALENT CANCERS GEOGRAPHIC REACH HIGHLY EXPERIENCED SALES FORCE FOCUSED ON THE COMMUNITY ONCOLOGIST & PATHOLOGIST MARKETS COMMERCIAL PRESENCE ESTIMATED REVENU

  9. Slide 9: Growing Relationships with Leading Biopharma Companies

    INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 9 2012 2013 2014 2015 $4M $30M +650% INCREASE IN SIGNED CONTRACTS & POTENTIAL REVENUES WITH BIOPHARMA CUSTOMERS 2012 TO 2015 BIOPHARMA CONTRACTS: FUTURE REVENUE GROWTH(1) (1) Approximate expected future re

  10. Slide 10: ICON Partnership

    INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 10  Global CRO industry leader specializing in Phase I through Phase IV clinical trial testing  $1.5B in net annual revenue & 11,000 employees  ICON has conducted over 950 oncology studies, assessing ov

  11. Slide 11: Collaborations with Premier Cancer Research Institutions

    INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 11 COLLABORATIONS WITH PREMIER CANCER RESEARCH INSTITUTIONS Disease Target Collaboration Highlights Beth Israel Deaconess Medical Ctr DLBCL (Diffuse Large B-Cell Lymphoma) Biomarker-based outcome predictio

  12. Slide 12: OncoSpire Genomics Joint Venture with Mayo Clinic

    INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 12 ONCOSPIRE GENOMICS JOINT VENTURE BETWEEN CANCER GENETICS & MAYO CLINIC  Joint venture based in Rochester, MN  Goal: to develop tests that will become the gold standard in diagnosing and managing patie

  13. Slide 13: Unique, Proprietary Portfolio of Genomic Tests & Panels

    INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 13 TISSUE OF ORIGIN™ (2) UROGENRA®-KIDNEY FHACT® CERVICAL FOCUS::CANCER HOTSPOT™ UNIQUE, PROPRIETARY PORTFOLIO OF GENOMIC TESTS & PANELS RESEARCH & DISCOVERY CLINICAL DEVELOPMENT COMMERCIAL DEVELOPMENT FOC

  14. Slide 14: MatBA drives improved insight for CLL

    INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 14 ® SOLUTION MatBA®-CLL/SLL STRATIFIES PATIENTS INTO 3 DISTINCT RISK GROUPS USING 20 BIOMARKERS: 38% OF CASES ARE FAVORABLE FALLING UNDER "WATCH & WAIT" APPROACH 8% OF UNFAVORABLE CASES MISSED BY FISH ARE

  15. Slide 15: UroGenRA-Kidney Guides Management & Treatment Selection

    INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 15 UroGenRA® - KIDNEY GUIDES MANAGEMENT & APPROPRIATE TREATMENT SELECTION  Patients with renal masses often undergo unnecessary nephrectomy for accurate diagnosis & experience delay in treatment  Over 15

  16. Slide 16: FHACT for Cervical Cancer Triage

    INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 16 55.0M PAP SMEARS 3.5M UNCLEAR/ ABNORMAL 2.0M BIOPSIES 13K CASES OF CANCER  Today, all HPV+ women with abnormal Pap results are referred for colposcopy  Several cervical cancer tests are available but

  17. Slide 17: Disease-Focused Patent Portfolio

    INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 17 Application Submitted Term Through 2022 Term Through 2023 Term Through 2027 Term Through 2029 Term Through 2030 Term Through 2031 2 US Patents | EU | India | Canada Mature B-Cell Neoplasms 3 US Patents

  18. Slide 18: Diversified and Growing Revenue Base

    INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 18 DIVERSIFIED AND GROWING REVENUE BASE 55% 43% 2% Full Year 2014 $10.2M 70% 25% 5% 1H 2015 $8.6M CGI’s business is not over-dependent on third party reimbursement. In 1H 2015, Medicare represented 6% and

  19. Slide 19: Strong Record of Continuous Growth

    INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 19 STRONG RECORD OF CONTINUOUS GROWTH REVENUE GROWTH BY YEAR / PERIOD ($ IN MILLIONS) $0.6 $2.7 $5.6 $6.0 $3.2 $3.7 $4.4 $2.1 $0.2 $0.4 $0.6 $0.3 $4.3 $6.6 $10.2 $8.6 2012 2013 2014 1H 2015 BIOPHARMA CLINI

  20. Slide 20: Pro Forma Revenue

    INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 20 $6.6 $19.8 $26.4 $10.2 $16.7 $26.9 $8.6 $7.7 $16.3 FY13 FY14 YTD 15 PROFORMA REVENUES CANCER GENETICS RESPONSE GENETICS PRO FORMA CANCER GENETICS’ AND RESPONSE GENETICS’ PRO FORMA REVENUE ($ IN MILLIONS

  21. Slide 21: Cancer Genetics Standalone Summary Statement of Operations

    INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 21 CANCER GENETICS STANDALONE SUMMARY STATEMENT OF OPERATIONS SUMMARIZED INCOME STATEMENTS (dollars in thousands) SUMMARIZED BALANCE SHEET (dollars in thousands) 1H, 2014 1H, 2015 REVENUE $2,942 8,555 Gros

  22. Slide 22: Historical Clinical Reimbursement Mix & Payer Coverage

    INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 22 COVERED LIVES REPRESENTED BY RECENT AGREEMENTS WITH NATIONAL INTEGRATED NETWORKS  America’s Choice Provider  Blue Cross Blue Shield of California  Blue Cross Blue Shield of Illinois  Blue Cross Blue

  23. Slide 23: Milestones Expected in Coming Quarters

    INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 23 MILESTONES EXPECTED IN COMING QUARTERS REIMBURSEMENT & MARKET ADOPTION  Increasing covered lives market access through add’l payers & health care organizations  Additional international agreements for

  24. Slide 24: Experienced Leadership Team

    INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 24 EXPERIENCED LEADERSHIP TEAM Panna Sharma Chief Executive Officer & President, Board Member Edward J. Sitar, CPA Chief Financial Officer & Treasurer Rita Shaknovich, MD, PhD Group Medical Director & VP,

  25. Slide 25: Board of Directors

    INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 25 BOARD OF DIRECTORS John Pappajohn Non-Executive Chairman Raju S.K. Chaganti, PhD Howard McLeod, PharmD g Panna Sharma Michael J. Welsh, MD c, g Geoffrey Harris, CFA a Ted Cannon a,c Franklyn Prendergast

  26. Slide 26: Investor Highlights

    INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 26 Large, Global Market Opportunities $458B GLOBAL ONCOLOGY SPEND BY 2030 Global Footprint Created by Highly Strategic M&A 3 TRANSFORMATIVE ACQUISITIONS IN 2014–2015 Strong & Growing Partnerships with Lead

  27. Slide 27: The Oncology Diagnostics Partner from Bench to Bedside

    INVESTOR PRESENTATION | 2015 CANCER GENETICS, INC. | WWW.CANCERGENETICS.COM | @CANCER_GENETICS 27 THE ONCOLOGY DIAGNOSTICS PARTNER FROM BENCH TO BEDSIDE CGI Headquarters 201 Route 17 North, 2nd Fl. Rutherford, NJ 07070 Phone: +1 201-528-9200 Fax: +1 201-528-9235 RUTHERFORD, NJ Research Triangle Park

Cancer Genetics — Investor Presentation (September 2015) on 6ix